96 related articles for article (PubMed ID: 9272300)
1. Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts.
Pelletier JP; Mineau F; Fernandes J; Kiansa K; Ranger P; Martel-Pelletier J
Clin Exp Rheumatol; 1997; 15(4):393-8. PubMed ID: 9272300
[TBL] [Abstract][Full Text] [Related]
2. Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Pelletier JP; McCollum R; Cloutier JM; Martel-Pelletier J
Br J Rheumatol; 1992; 31 Suppl 1():19-26. PubMed ID: 1555050
[TBL] [Abstract][Full Text] [Related]
3. Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans.
Yang SF; Hsieh YS; Lue KH; Chu SC; Chang IC; Lu KH
Clin Biochem; 2008 Jan; 41(1-2):109-16. PubMed ID: 17996201
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis.
Nonaka T; Kikuchi H; Ikeda T; Okamoto Y; Hamanishi C; Tanaka S
J Rheumatol; 2000 Apr; 27(4):997-1004. PubMed ID: 10782829
[TBL] [Abstract][Full Text] [Related]
5. Naproxen, meloxicam and methylprednisolone inhibit urokinase plasminogen activator and inhibitor and gelatinases expression during the early stage of osteoarthritis.
Chu SC; Yang SF; Lue KH; Hsieh YS; Li TJ; Lu KH
Clin Chim Acta; 2008 Jan; 387(1-2):90-6. PubMed ID: 17963739
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of nonsteroidal antiinflammatory drugs on the IL-1 altered expression of plasminogen activators and plasminogen activator inhibitor-1 by articular chondrocytes.
Sadowski T; Steinmeyer J
Inflamm Res; 2002 Aug; 51(8):427-33. PubMed ID: 12234061
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
8. Independent regulation of plasminogen activator inhibitor 2 and plasminogen activator inhibitor 1 in human synovial fibroblasts.
Hamilton JA; Cheung D; Filonzi EL; Piccoli DS; Wojta J; Gallichio M; McGrath K; Last K
Arthritis Rheum; 1992 Dec; 35(12):1526-34. PubMed ID: 1472130
[TBL] [Abstract][Full Text] [Related]
9. Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage.
Pelletier JP; Martel-Pelletier J
Drugs; 1993; 46 Suppl 1():34-9. PubMed ID: 7506192
[TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 by grape seed proanthocyanidin extract.
Sandra D; Radha M; Harishkumar M; Yuichi N; Sayuri O; Masugi M
Phytomedicine; 2010 Jan; 17(1):42-6. PubMed ID: 19640694
[TBL] [Abstract][Full Text] [Related]
12. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
14. Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis.
Diehl P; Hantke B; Hennig M; Tschesche H; Mittelmeier W; Schmitt M; Muehlenweg B
Int J Mol Med; 2004 May; 13(5):711-5. PubMed ID: 15067375
[TBL] [Abstract][Full Text] [Related]
15. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts.
Hilal G; Martel-Pelletier J; Pelletier JP; Duval N; Lajeunesse D
Arthritis Rheum; 1999 Oct; 42(10):2112-22. PubMed ID: 10524682
[TBL] [Abstract][Full Text] [Related]
16. Effects of intra-articular administration of sodium hyaluronate on plasminogen activator system in temporomandibular joints with osteoarthritis.
Tang YL; Zhu GQ; Hu L; Zheng M; Zhang JY; Shi ZD; Liang XH
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr; 109(4):541-7. PubMed ID: 20185343
[TBL] [Abstract][Full Text] [Related]
17. Effects of nimesulide and sodium diclofenac on interleukin-6, interleukin-8, proteoglycans and prostaglandin E2 production by human articular chondrocytes in vitro.
Henrotin YE; Labasse AH; Simonis PE; Zheng SX; Deby GP; Famaey JP; Crielaard JM; Reginster JY
Clin Exp Rheumatol; 1999; 17(2):151-60. PubMed ID: 10342040
[TBL] [Abstract][Full Text] [Related]
18. Control of the chondrocyte fibrinolytic balance by the drug piroxicam: relevance to the osteoarthritic process.
Fibbi G; Serni U; Matucci A; Mannoni A; Pucci M; Anichini E; Del Rosso M
J Rheumatol; 1994 Dec; 21(12):2322-8. PubMed ID: 7699636
[TBL] [Abstract][Full Text] [Related]
19. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
20. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
